News

New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.

Researchers investigated the link between psychosis, criminal sanctions, and mortality rates following discharge from a hospital for acute psychosis.

Would you like to be featured in an upcoming print issue? Submit an article on child & adolescent psychiatry!

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

Extreme risk protection orders may be an effective suicide prevention tool.

What are the psychological challenges of this upcoming holiday season?

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way.

Top stories from the weekend highlighted heroes and villains and underlined the need to address mental health.

In some cases of child murder by the mother, psychiatrists may have a critical role in prevention. Learn more here.

Catch up on coverage from the 63rd Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona.

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

"Here the body’s art conspires with destruction..."

What if biomarkers could tell you whether or not a depression treatment would work before a patient started?

How can Ibogaine help patients with Alcohol Use Disorder, specifically in veterans?

What effects do lifestyle factors have on brain aging and neuropsychiatic symptoms?

A psychiatrist becomes a Swiftie after exploring the positive psychiatric attributes from her music.

"Each wound contains its own beauty..."

Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.

Negative symptoms pose significant challenges for individuals with schizophrenia and their caregivers.

As the Terminally Ill Adults Bill moves through parliament, government representatives and doctors alike consider the effects legalization may have on patients of psychiatrists.

A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.

Machine learning may help science better understand cognitive impairment in schizophrenia and improve prevention and patient care.

Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms? Learn more in this ACNP 2024 Annual Meeting session!

How can we prevent heat-related illness in patients with psychiatric disorders, who are more vulnerable to heat?

Thomas R. Kosten, MD, shares thoughts on the latest schizophrenia genetic model research presented at the meeting.

Check out 2 new psychopharmacology innovations!

Psychiatry: one of the most dynamic and rapidly evolving specialties in medicine.

New research links reduced synaptic density,early psychosis, and cannabis use, offering insights into negative symptoms and potential interventions.

Stephanie Gorka, PhD, shared findings at the ACNP Annual Meeting on orexin receptor agonists addressing AUDs.